Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
GADD45A is a mediator of mitochondrial loss, atrophy, and weakness in skeletal muscle
George R. Marcotte, Matthew J. Miller, Hawley E. Kunz, Zachary C. Ryan, Matthew D. Strub, Patrick M. Vanderboom, Carrie J. Heppelmann, Sarah Chau, Zachary D. Von Ruff, Sean P. Kilroe, Andrew T. McKeen, Jason M. Dierdorff, Jennifer I. Stern, Karl A. Nath, Chad E. Grueter, Vitor A. Lira, Andrew R. Judge, Blake B. Rasmussen, K. Sreekumaran Nair, Ian R. Lanza, Scott M. Ebert, Christopher M. Adams
George R. Marcotte, Matthew J. Miller, Hawley E. Kunz, Zachary C. Ryan, Matthew D. Strub, Patrick M. Vanderboom, Carrie J. Heppelmann, Sarah Chau, Zachary D. Von Ruff, Sean P. Kilroe, Andrew T. McKeen, Jason M. Dierdorff, Jennifer I. Stern, Karl A. Nath, Chad E. Grueter, Vitor A. Lira, Andrew R. Judge, Blake B. Rasmussen, K. Sreekumaran Nair, Ian R. Lanza, Scott M. Ebert, Christopher M. Adams
View: Text | PDF
Research Article Metabolism Muscle biology

GADD45A is a mediator of mitochondrial loss, atrophy, and weakness in skeletal muscle

  • Text
  • PDF
Abstract

Aging and many illnesses and injuries impair skeletal muscle mass and function, but the molecular mechanisms are not well understood. To better understand the mechanisms, we generated and studied transgenic mice with skeletal muscle–specific expression of growth arrest and DNA damage inducible α (GADD45A), a signaling protein whose expression in skeletal muscle rises during aging and a wide range of illnesses and injuries. We found that GADD45A induced several cellular changes that are characteristic of skeletal muscle atrophy, including a reduction in skeletal muscle mitochondria and oxidative capacity, selective atrophy of glycolytic muscle fibers, and paradoxical expression of oxidative myosin heavy chains despite mitochondrial loss. These cellular changes were at least partly mediated by MAP kinase kinase kinase 4, a protein kinase that is directly activated by GADD45A. By inducing these changes, GADD45A decreased the mass of muscles that are enriched in glycolytic fibers, and it impaired strength, specific force, and endurance exercise capacity. Furthermore, as predicted by data from mouse models, we found that GADD45A expression in skeletal muscle was associated with muscle weakness in humans. Collectively, these findings identify GADD45A as a mediator of mitochondrial loss, atrophy, and weakness in mouse skeletal muscle and a potential target for muscle weakness in humans.

Authors

George R. Marcotte, Matthew J. Miller, Hawley E. Kunz, Zachary C. Ryan, Matthew D. Strub, Patrick M. Vanderboom, Carrie J. Heppelmann, Sarah Chau, Zachary D. Von Ruff, Sean P. Kilroe, Andrew T. McKeen, Jason M. Dierdorff, Jennifer I. Stern, Karl A. Nath, Chad E. Grueter, Vitor A. Lira, Andrew R. Judge, Blake B. Rasmussen, K. Sreekumaran Nair, Ian R. Lanza, Scott M. Ebert, Christopher M. Adams

×

Figure 9

Skeletal muscle GADD45A expression is associated with muscle weakness in humans.

Options: View larger image (or click on image) Download as PowerPoint
Skeletal muscle GADD45A expression is associated with muscle weakness in...
(A–E) Human participants who were 20 to 35 years old (young) or 65 to 85 years old (old) volunteered for a study in which GADD45A mRNA levels in the vastus lateralis muscle were assessed by RNA sequencing and muscle function was assessed by measurement of maximal knee extensor strength and peak power. Each data point represents the value from 1 participant. See Supporting Data Values file. (A) GADD45A mRNA levels. (B) Maximal leg strength, assessed via 1 repetition maximum (1 RM) leg extension, a dynamic movement through a full range of motion of knee extension. (C) Peak leg power production. (A–C) Horizontal bars indicate mean values, and P values were determined with unpaired 2-tailed t tests. (D and E) Correlation of GADD45A mRNA levels to maximal leg strength (D) and peak leg power (E). (F–H) Human participants aged 50 to 63 years old volunteered for a study using a model of disuse muscle atrophy. In each participant, one leg was immobilized with a leg brace for 7 days, and the contralateral leg remained mobile and served as an intra-individual control. In both legs, maximal leg strength and GADD45A mRNA in the vastus lateralis muscle were quantified at baseline (day 0, prior to unilateral leg immobilization) and again on day 7 (after unilateral leg immobilization). Each data point represents the fold change (day 7/day 0) from the mobile or immobile leg, as indicated. (F and G) Fold-change in GADD45A mRNA levels (F) and maximal leg strength (G). Horizontal bars indicate mean values. P values were determined with paired 2-tailed t tests. (H) Correlation of GADD45A mRNA to maximal leg strength. (D, E, and H) Pearson’s correlation coefficient and P value were determined with simple linear regression. RPKM, reads per kilobase million.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts